Ligand Pharmaceuticals Incorporated - Common Stock (LGND)
117.36
+0.05 (0.04%)
Ligand Pharmaceuticals is a biopharmaceutical company that focuses on the development of innovative therapies and treatments by leveraging its proprietary drug discovery technologies and a diverse portfolio of drug candidates
The company primarily collaborates with other pharmaceutical and biotechnology firms to discover and advance new medications, particularly in areas such as oncology, cardiovascular diseases, and metabolic disorders. Through its unique platform, Ligand aims to enhance drug efficacy and streamline the development process, contributing to the advancement of healthcare solutions that improve patient outcomes.
Small-cap stocks could get a boost from the central bank's anticipated rate cuts in 2025. These three stocks may be a great way to get ahead of this catalyst.
While the tech sector has led the Q1 earnings season, investors shouldn’t overlook these top medical stocks. To that point, the growth and expansion of Ligand Pharmaceuticals, Oscar Health, and Penumbra is hard to ignore.
Ligand Pharmaceuticals beats Q4 2023 sales estimates at $28.1 million, with strong core Captisol and royalty figures. CEO Todd Davis highlights transformative 2023 and optimistic guidance for 2024.
